<DOC>
	<DOCNO>NCT02634411</DOCNO>
	<brief_summary>Ventilator-associated pneumonia ( VAP ) account 25 % infection intensive care unit ( Réseau RAISIN 2012 ) . A short duration ( 8 day ; SD ) vs. long duration ( 15 day ; LD ) antibiotic therapy comparable clinical efficacy less antibiotic use less multidrug-resistant pathogen ( MDR ) emergence . These result lead American Thoracic Society recommend SD therapy VAP , exception document VAP non-fermenting Gram negative bacillus ( NF-GNB ) , include Pseudomonas aeruginosa ( PA-VAP ) , due absence study focus specifically PA-VAP . Thus beneficial effect SD therapy PA-VAP still matter debate . In small ( n=127 ) subgroup analysis , high rate recurrence SD therapy ( n=21 , 32.8 % ) observe compare LD therapy group ( n=12 , 19.0 % ) . Unfortunately , definition recurrence essentially base microbiological rather clinical data , high rate recurrence observe could rather reflect high rate colonization new infection . Interestingly , trend low rate mortality also observe SD group ( n=15 , 23.4 % ) compare LD group ( n=19 , 30.2 % ) , study clearly underpowered detect difference mortality group . The two strategy consider different , risk mortality recent meta-analysis , perform available study ( n=2 ) , ( OR = 1.33 , 95 % CI [ 0.33 5.26 ] SD vs. LD strategy respectively ) . However , conclusion remain questionable consider large confidence interval risk power study . Primary objective assessment criterion : To assess non-inferiority short duration antibiotic ( 8 day ) vs. prolong antibiotic therapy ( 15 day ) P. aeruginosa ventilator-associated pneumonia ( PA-VAP ) composite end-point combine Day-90 mortality PA-VAP recurrence rate hospitalization ICU . Study Design : Randomized , open-labeled non inferiority control trial 32 French Intensive Care Units participate study Research period : Total study duration : 27 month Inclusion period : 24 month Duration participation patient : 90 day</brief_summary>
	<brief_title>Impact Duration Antibiotics Clinical Events Patients With Pseudomonas Aeruginosa Ventilator-associated Pneumonia ( iDIAPASON )</brief_title>
	<detailed_description>Ventilator-associated pneumonia ( VAP ) major cause morbidity mortality ICU , account 25 % infection intensive care unit ( Réseau RAISIN 2012 ) . From 1975 2003 , incidence hospital-acquired pneumonia cause Pseudomonas aeruginosa ( PA ) almost double , 9.6 % 18.1 % . In US national large-scale survey , PA frequently isolate gram-negative aerobic bacterium ICUs ( 23 % ) also frequent bacterium isolate respiratory tract ( 31.6 % ) . PA-VAP associated high mortality range 40 % 69 % , high rate recurrence despite adequate antimicrobial therapy . In large randomized trial regard optimal duration antibiotic therapy overall VAPs , rate recurrence among subgroup non-fermenting Gram negative bacillus ( NF-GNB ) document VAP vary 19.0 % 32.8 % , accord randomization arm . Finally , recently publish cohort 393 PA-VAP 314 patient , composite criterion failure treatment ( death recurrence ) occur 112 case ( 28.5 % ) . Hypothesis A short duration antibiotherapy ( 8 day ) vs. long duration antibiotherapy ( 15 day ) treatment Pseudomonas aeruginosa Ventilator-Associated Pneumonia ( PA-VAP ) safe associate increased mortality recurrence rate PA-VAP . The demonstration hypothesis could lead decrease antibiotic exposure hospitalization Intensive Care Unit ( ICU ) turn reduce acquisition spread multidrug-resistant pathogen ( MDR ) . Objectives 1 . Primary objective To assess non-inferiority short duration antibiotic ( 8 day ) vs. prolong antibiotic therapy ( 15 day ) Pseudomonas aeruginosa ventilator-associated pneumonia ( PA-VAP ) morbi-mortality 90 day . 2 . Secondary objective To compare short long duration antibiotic : - mortality ICU - morbidity ICU ( mechanical ventilation , duration hospitalization ) - exposure acquisition MDR hospitalization - number type extrapulmonary infection Plan research 1 . Concise description primary secondary assessment criterion - Primary assessment criterion : A composite endpoint combine Day-90 mortality PA-VAP recurrence rate hospitalization ICU ( within 90 day ) . Recurrence define posteriori 3 independent expert predefined criterion : clinical suspicion VAP ( ≥ two criterion include : fever &gt; 38.5 ° C , leukocytosis &gt; 109/L leukopenia &lt; 4.108/L , purulent tracheobronchial secretion new persistent infiltrate chest radiography ) associate positive quantitative culture respiratory sample ( bronchoalveolar lavage fluid ( significant threshold ≥104 colony-forming units/mL ) plug telescopic catheter ( significant threshold ≥103 colony-forming units/mL ) quantitative endotracheal aspirate distal pulmonary secretion sample ( significant threshold ≥106 colony-forming units/mL ) ) . - Secondary assessment criterion : 1 . D30 D90 mortality rate ( % ) 2 . Morbidity : Duration mechanical ventilation ( day ) Duration hospitalization ICU ( day ) 3 . Exposure antibiotic hospitalization ICU ( day ) 4 . Number type extrapulmonary infection hospitalization ICU ( n ) 5 . Acquisition MDR hospitalization ICU ( swab sample rectum anterior naris ) 2 . Description research methodology Randomized , open-labeled non inferiority trial compare parallel group : - 8 day antibiotic therapy - 15 day antibiotic therapy Antibiotic therapy Antibiotic treatment start realization bacteriological sampling , without wait result . The choice initial antibiotic therapy leave discretion physician essentially base clinical context , previously antibiotic therapy , presence absence risk factor MDR ( antibiotic hospitalization previous 90 day , current hospitalization ≥ 5 day , MV ≥ 5 day , supported dialysis center residency nurse home ) , local epidemiological data , finally patient already know colonize MDR . Investigators would strongly encourage convert initial regimen narrow- spectrum therapy , base culture result . All antibiotic would withdraw , either end day 8 day 15 , accord randomization assignment , except prescribe documented pulmonary infection recurrence day . An algorithm initial prescription antibiotic establish ICU , algorithm adapt whenever necessary change local ecology . Number centre participate 32 french Intensive Care Units ( ICUs )</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Ventilator-Associated</mesh_term>
	<mesh_term>Pseudomonas Infections</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Antibiotics , Antitubercular</mesh_term>
	<criteria>Patients older 18 year Mechanical ventilation ≥ 48 hour Documented Pseudomonas aeruginosa ventilatorassociated pneumonia : Clinical suspicion ( ≥ two criterion include : fever &gt; 38.5°C , leukocytosis &gt; 109/L leukopenia &lt; 4.108/L , purulent tracheobronchial secretion new persistent infiltrate chest radiography ) . Documented Pseudomonas aeruginosa positive quantitative culture respiratory sample : bronchoalveolar lavage fluid ( significant threshold , &gt; 104cfu/ml ) plug telescopic catheter ( significant threshold , &gt; 103cfu/ml ) quantitative endotracheal aspirate ( significant threshold , &gt; 106cfu/ml ) . Written informed consent Patient affiliate French social security Immunocompromised patient ( HIV , immunosuppressive therapy , corticosteroid &gt; 0.5 mg / kg per day month ) Patients receive antibiotic therapy extrapulmonary infection Patients procedure withdraw lifesustaining treatment establish Pregnancy Patients include another interventional study Chronic pulmonary colonization Pseudomonas aeruginosa : patient Chronic Obstructive Pulmonary Disease ( COPD ) bronchiectasis , positive respiratory sample infra threshold rate Pseudomonas aeruginosa ( ie &lt; 103 CFUs/mL protect specimen brush &lt; 106 CFUs/mL tracheal aspirate ) , obtain absence pneumonia exacerbation 6 month ICU admission . Patient guardianship curatorship</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Ventilator Associated</keyword>
	<keyword>Pneumonia</keyword>
	<keyword>Antibiotic treatment</keyword>
	<keyword>Pseudomonas aeruginosa</keyword>
</DOC>